Evidence map›Paper›PMID 36092714›Full record

ArticleFrontiers in cell and developmental biology2022

Transcriptional comparison of adult human primary Retinal Pigment Epithelium, human pluripotent stem cell-derived Retinal Pigment Epithelium, and ARPE19 cells.

Elke K Markert, Holger Klein, Coralie Viollet, Werner Rust, Benjamin Strobel, Stefan G Kauschke, Bar Makovoz, Heike Neubauer, Remko A Bakker, Timothy A Blenkinsop

Abstract read
In one paragraph

Article in Frontiers in cell and developmental biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. A Sulfated Polysaccharide fromMarine drugs · 2025
    Article
  11. Article
  12. Article
  13. Complement C3 Activation in the Human Retinal Pigment Epithelium.Investigative ophthalmology & visual science · 2025
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Elke K MarkertGlobal Computational Biology and Digital Sciences, Boehringer Ingelheim Pharma GmbH, Biberach, Germany.
Holger KleinGlobal Computational Biology and Digital Sciences, Boehringer Ingelheim Pharma GmbH, Biberach, Germany.
Coralie ViolletGlobal Computational Biology and Digital Sciences, Boehringer Ingelheim Pharma GmbH, Biberach, Germany.
Werner RustGlobal Computational Biology and Digital Sciences, Boehringer Ingelheim Pharma GmbH, Biberach, Germany.
Benjamin StrobelTranslational Medicine and Clinical Pharmacology, Boehringer Ingelheim Pharma GmbH, Biberach, Germany.
Stefan G KauschkeCardioMetabolic Diseases Research, Boehringer Ingelheim Pharma GmbH, Biberach, Germany.
Bar MakovozOphthalmology Cell Development and Regenerative Biology, Black Family Stem Cell Institute, Icahn School of Medicine at Mount Sinai, New York, NY, United States.
Heike NeubauerCardioMetabolic Diseases Research, Boehringer Ingelheim Pharma GmbH, Biberach, Germany.
Remko A BakkerCardioMetabolic Diseases Research, Boehringer Ingelheim Pharma GmbH, Biberach, Germany.
Timothy A BlenkinsopOphthalmology Cell Development and Regenerative Biology, Black Family Stem Cell Institute, Icahn School of Medicine at Mount Sinai, New York, NY, United States.

Funding

Reversing Contractility in Epiretinal MembranesR01EY029736 · NEI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI BLENKINSOP, TIMOTHY A. · 2020 to 2024
$2.0M
Transcriptional regulators of iris muscle cell developmentR21EY030215 · NEI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI BLENKINSOP, TIMOTHY A. · 2020 to 2021
$457k
NEI NIH HHS R01 EY029736NEI NIH HHS R21 EY030215
6 · The paper itself

Abstract

The therapeutic potential of pluripotent stem cells is great as they promise to usher in a new era of medicine where cells or organs may be prescribed to replace dysfunctional tissue. At the forefront are efforts in the eye to develop this technology as it lends itself to

Indexed as

age-related macular degenerationARPE-19epithelial to mesenchymal transitioniPSC-RPEproliferative vitreoretinopathyretinal pigment epitheliumRNA-sequencingtransplantation

Identifiers

PMID36092714
PMCPMC9461284

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.